• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD medication For adhd and depression During Pregnancy and Breastfeeding

The choice of whether to stop or continue ADHD medications during pregnancy and nursing is a difficult decision for women suffering from the condition. There aren't many studies on how long-term exposure may affect the foetus.

A study recently published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological issues like hearing loss or vision, febrile seizures, or IQ impairment. The authors acknowledge that more high-quality studies are required.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medications need to balance the benefits of using them against the risks to the foetus. Doctors don't have enough data to make unambiguous recommendations however they can provide information about risks and benefits to help pregnant women make an informed decision.

A study published in Molecular Psychiatry concluded that women who were taking ADHD medication in early pregnancy were not at a higher risk of fetal malformations, or structural birth defects. Researchers conducted a large population-based case control study to examine the prevalence of major structural defects in infants born to mothers who took stimulants during pregnancy. Clinical geneticists and pediatric cardiologists reviewed the cases to ensure accurate case classification and to limit the chance of bias.

The study conducted by the researchers had some limitations. The researchers were not able in the beginning to distinguish the effects caused by the medication from the disorder. That limitation makes it difficult to know whether the small differences observed in the groups that were exposed are due to the use of medication or the confounding effect of comorbidities. The researchers did not study long-term outcomes for offspring.

The study found that infants whose mother had taken ADHD medication during pregnancy were at a slightly greater risk of being admitted to the neonatal care unit (NICU) as compared to mothers who did not take any medication during pregnancy, or had discontinued taking their medication prior to or during pregnancy. This increase was due to central nervous system-related disorders, and the increased risk for admission was not found to be influenced by which stimulant medications were used during pregnancy.

Women who took stimulant ADHD medications during pregnancy also had a higher chance of having to have an emergency caesarean section or having one whose baby scored low on the Apgar scale (less than 7). These increases did not appear to be affected by the kind of medication used during pregnancy.

Researchers suggest that the minor risks posed by the use of ADHD medications during early pregnancies can be offset by more beneficial outcomes for both baby and mother of continued treatment for the woman's condition. Physicians should discuss the issue with their patients and, where they are able, assist them in developing strategies to improve coping skills which can reduce the impact of her disorder on her daily functioning and relationships.

Interactions with Medication

More and more doctors are faced with the decision of whether to continue treatment or stop as more women are diagnosed with ADHD. These decisions are usually taken without clear and authoritative evidence. Instead, physicians must weigh their own knowledge and experience, as well as the experiences of other doctors and the research on the subject.

In particular, the issue of potential risks for the baby can be a challenge. The research that has been conducted on this topic is based on observations rather than controlled studies, and many of the findings are contradictory. Most studies focus on live births, which can underestimate the teratogenic impact that can lead to terminations or abortions of pregnancy. The study that is discussed in this journal club addresses these issues by analyzing data on live and deceased births.

The conclusion is that while some studies have shown that there is a positive correlation between ADHD medications and the risk of certain birth defects, other studies have not found any evidence of a link, and most studies demonstrate a neutral or slightly negative effect. In every case, a careful analysis of the risks and benefits must be performed.

It can be challenging, if not impossible for women suffering from ADHD to stop taking their medication. In fact, in an article recently published in the Archives of Women's Mental Health psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can cause depression, feelings of loneliness and family conflict for these patients. A decrease in medication could also impact the ability to safely drive and perform work-related tasks, which are vital aspects of everyday life for people with ADHD.

She suggests that women who are unsure whether to continue taking the medication or stop it due to their pregnancy, educate their family members, coworkers, and acquaintances about the condition, its impact on daily functioning and the benefits of continuing the current treatment plan. It can also help a woman feel supported in her decision. It is also worth noting that some medications are able to pass through the placenta so if a woman decides to stop taking her ADHD medication during pregnancy and breastfeeding, she should be aware that traces of the drug can be transferred to the infant.

Birth Defects and Risk of

As the use of ADHD drugs to treat symptoms of attention deficit hyperactivity disorder (ADHD) grows, so do concerns about the effects that the drugs might have on foetuses. A study that was published in the journal Molecular Psychiatry adds to the existing information on this topic. Utilizing two huge data sets, researchers were able to examine more than 4.3 million pregnancies and determine whether the use of stimulant medications increased the risk of birth defects. Although the risk overall remains low, the scientists did find that first-trimester exposure to ADHD medications was linked to an increased risk of specific heart defects, such as ventriculoseptal defect (VSD).

The researchers of the study found no connection between early medication use and other congenital abnormalities, such as facial clefting or club foot. The findings are in line with previous studies showing the presence of a small, but significant increase in the risk of cardiac malformations among women who began taking ADHD medications before pregnancy. This risk increased during the latter part of pregnancy when many women began to stop taking their medication.

Women who took ADHD medication in the first trimester were more likely to need a caesarean or have an insufficient Apgar after birth and have a baby who needed help breathing when they were born. The authors of the study were unable to eliminate selection bias because they limited their study to women who did not have any other medical conditions that could have contributed to the findings.

The researchers hope their study will serve to inform the clinical decisions of doctors who treat pregnant women. The researchers suggest that while discussing the risks and benefits are important, the decision on whether to continue or stop medication should be made according to the severity of each woman's ADHD symptoms and her requirements.

The authors also caution that, while stopping the medication for adhd and odd is an alternative, it is not a recommended practice because of the high prevalence of depression and other mental health problems in women who are pregnant or who are recently postpartum. Further, research shows that women who stop taking their medications will have a tough transitioning to life without them after the baby is born.

Nursing

The responsibilities of being a new adhd medication mother can be overwhelming. Women with ADHD can face severe challenges when they must manage their symptoms, go to doctor appointments, prepare for the birth of a baby and adjust to a new routine. As such, many women decide to continue taking their ADHD medication throughout the pregnancy.

The majority of stimulant drugs are absorbed through breast milk in very small amounts, so the risk to the breastfeeding infant is minimal. The rate of medication exposure will vary based on the dosage and frequency of administration as well as the time of day. Additionally, different medications enter the infant's system differently through the gastrointestinal tract as well as breast milk, and the effect of this on a newborn isn't fully understood.

Because of the lack of research, some physicians may be inclined to discontinue stimulant medications during the course of pregnancy. This is a difficult decision for the patient, who must balance the benefits of keeping her medication against the possible risks to the fetus. In the meantime, until more information is available, doctors should ask all pregnant patients about their experience with ADHD and whether they are planning or taking to take medication during the perinatal time.

A growing number of studies have shown that most women can safely continue to take their ADHD medication during pregnancy and while breastfeeding. This has led to more and more patients are choosing to do so and, in consultation with their physician, they have found that the benefits of keeping their current medication far outweigh any risks.

It is essential for women with ADHD who are contemplating breastfeeding to seek a specialist psychiatrist's advice prior becoming pregnant. They should discuss their medication with their physician and discuss the advantages and disadvantages of continuing treatment, including non-pharmacological management strategies. Psychoeducation is also required to help pregnant women with ADHD be aware of the symptoms and underlying disorder. They should also be informed about treatment options and strengthen coping mechanisms. This should include a multidisciplinary approach, which includes the GP doctors, obstetricians and psychiatrists. Pregnancy counseling should include discussion of a treatment plan for the mother and the child, monitoring of signs of deterioration, and, if needed modifications to the medication regimen.